These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. A practical review on carfilzomib in multiple myeloma. Muchtar E; Gertz MA; Magen H Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241 [TBL] [Abstract][Full Text] [Related]
27. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405 [TBL] [Abstract][Full Text] [Related]
28. Targets for Ibrutinib Beyond B Cell Malignancies. Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359 [TBL] [Abstract][Full Text] [Related]
29. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention. Kupisiewicz K Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989 [TBL] [Abstract][Full Text] [Related]
30. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945 [TBL] [Abstract][Full Text] [Related]
31. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Garcia-Gomez A; Quwaider D; Canavese M; Ocio EM; Tian Z; Blanco JF; Berger AJ; Ortiz-de-Solorzano C; Hernández-Iglesias T; Martens AC; Groen RW; Mateo-Urdiales J; Fraile S; Galarraga M; Chauhan D; San Miguel JF; Raje N; Garayoa M Clin Cancer Res; 2014 Mar; 20(6):1542-54. PubMed ID: 24486586 [TBL] [Abstract][Full Text] [Related]
32. Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib. Shen X; Wu C; Lei M; Yan Q; Zhang H; Zhang L; Wang X; Yang Y; Li J; Zhu Y; Chen L Cell Death Dis; 2021 Apr; 12(5):429. PubMed ID: 33931582 [TBL] [Abstract][Full Text] [Related]
33. Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. Li X; Zuo Y; Tang G; Wang Y; Zhou Y; Wang X; Guo T; Xia M; Ding N; Pan Z J Med Chem; 2014 Jun; 57(12):5112-28. PubMed ID: 24915291 [TBL] [Abstract][Full Text] [Related]
34. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575 [TBL] [Abstract][Full Text] [Related]
35. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464 [TBL] [Abstract][Full Text] [Related]
36. Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in Borsi E; Martello M; Santacroce B; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Rocchi S; Cavo M; Terragna C Haematologica; 2018 Dec; 103(12):e602-e606. PubMed ID: 30026343 [No Abstract] [Full Text] [Related]
37. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649 [TBL] [Abstract][Full Text] [Related]
38. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079 [TBL] [Abstract][Full Text] [Related]
39. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Missbach M; Jeschke M; Feyen J; Müller K; Glatt M; Green J; Susa M Bone; 1999 May; 24(5):437-49. PubMed ID: 10321903 [TBL] [Abstract][Full Text] [Related]
40. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing. Wang Z; Dove P; Wang X; Shamas-Din A; Li Z; Nachman A; Oh YJ; Hurren R; Ruschak A; Climie S; Press B; Griffin C; Undzys E; Aman A; Al-awar R; Kay LE; O'Neill D; Trudel S; Slassi M; Schimmer AD Cell Death Dis; 2015 Jul; 6(7):e1815. PubMed ID: 26158521 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]